

# eInvest Better Future Fund (Managed Fund)

ASX:IMPQ  
MONTHLY REPORT SEPTEMBER 2022

	Month (%)	Quarter (%)	1 Year (%)	2 Year (%p.a)	Since Inception <sup>^</sup> (% p.a.)	Since Inception Cumulative <sup>^</sup> (%)
eInvest Better Future Fund (Managed Fund)	-8.7	-2.7	-24.1	+2.4	+4.9	+17.3
S&P/ASX Small Ordinaries Accum. Index	-11.2	-0.5	-22.6	+0.5	+0.1	+0.4
<b>Value Added (Detracted)</b>	<b>+2.5</b>	<b>-2.2</b>	<b>-1.5</b>	<b>+1.9</b>	<b>+4.8</b>	<b>+16.9</b>

<sup>^</sup>Inception date was 23 May 2019. Performance shown above are net of fees. Fund returns are calculated using net asset value per unit at the start and end of the specified period and do not reflect the brokerage or the bid ask spread that investors incur when buying and selling units on the ASX. Past performance is not a reliable indicator of future performance.

## Overview

- The benchmark fell 11.2% in September due to concerns over global growth as central banks continued to increase interest rates. The Fund finished the month down 8.7%, outperforming the benchmark by 2.5%.
- It is over three years since the inception of the Fund. It is a key goal of the Fund to demonstrate that there is no performance trade-off to invest for shaping a better future. Since inception, the Fund has delivered a +4.9% p.a. return net of fees, outperforming the benchmark by +4.8% p.a.
- Positive contributors to relative performance this month included Meridian Energy (+0.2%), Micro-X (+37.5%), APM Human Services (+0.6%) and EQT Holdings (-2.7%).
- Negative contributors this month included Telix Pharmaceuticals (-23.7%), HealthCo Healthcare & Wellness REIT (-21.7%), Iress (-21.1%) and Arena REIT (-20.7%).

## eInvest Better Future Fund (Managed Fund)

The aim of IMPQ is to grow the value of your investment over the long term by investing in companies predominantly outside the S&P/ASX Top 50 Index that conduct business taking into account environmental, social and governance ("ESG") considerations and/or conduct business in industries which have favourable characteristics having regard to ESG considerations. IMPQ seeks to provide a total return (after fees) that exceeds the S&P/ASX Small Ordinaries Accumulation Index.

### Portfolio Manager

Damian Cottier

### IMPQ FUM

\$34 million

### Distribution Frequency

Annually (if any)

### Management Cost


0.99% (incl of GST and RITC)

### Inception Date

23 May 2019

+ performance fee

## Portfolio's contribution to UN Sustainable Development Goals



Total Contribution: 67.33%

(equal to 54.83% social impact contribution and 12.5% environmental impact contribution)

Source: Data provided by the Sustainable Platform 30 September 2022; based on company revenues, based off the portfolio of the Better Future Fund

**eInvest Better Future Fund (ASX:IMPQ) – Monthly Report September 2022**

## Better Future Highlight


During September, portfolio holding Janison Education announced that it had been awarded a global agreement with Cambridge University Press and Assessment ("CUPA"). Janison's Insights online assessment platform is used for high-stakes and large scale online exams.

The three-year umbrella agreement is a validation of Janison's products after having worked with CUPA to deliver the Selective Schools and Opportunity Class entrance examinations for the NSW Department of Education and recently extended the relationship to the Cambridge Boxhill Language Assessment. This test is the global leader in English language testing for healthcare professionals.

The new agreement was signed with Cambridge's global headquarters in the UK and will encompass further online assessments with the first new examinations expected to be launched in UK and Europe in 2023.

Interestingly, Cambridge University Press published its first book in 1584, making it the oldest publishing house in the world and Cambridge Assessment was established in 1858.

## Sector Active Exposure vs Index



## Fund Review

The benchmark fell 11.2% in September due to concerns over global growth as central banks continued to increase interest rates. The Fund finished the month down 8.7%, outperforming the benchmark by 2.5%.

It is over three years since the inception of the Fund. It is a key goal of the Fund to demonstrate that there is no performance trade-off to invest for shaping a better future. Since inception, the Fund has delivered a +4.9% p.a. return net of fees, outperforming the benchmark by +4.8% p.a.

Positive contributors to relative performance this month included Meridian Energy (+0.2%), Micro-X (+37.5%), APM Human Services (+0.6%) and EQT Holdings (-2.7%).

Negative contributors this month included Telix Pharmaceuticals (-23.7%), HealthCo Healthcare & Wellness REIT (-21.7%), Iress (-21.1%) and Arena REIT (-20.7%).

Micro-X, which has developed an innovative X-ray nanotube technology, announced that it had formed a strategic relationship with Varex Imaging Corporation, the largest independent manufacturer of x-ray components globally. Micro-X agreed to provide an exclusive global licence to Varex to use Micro-X's technology in multi-beam x-ray tubes for \$7.5m. This is an application of the technology that is not used in the company's existing products or development plan. In addition, Varex agreed to take a 9.9% equity stake in Micro-X at a 10% premium to the pre-transaction price. Later in the month, Micro-X announced that it had been awarded an extension on its development contract with the US Department of Homeland Security ("DHS") for a Miniature Baggage Scanner and that DHS had also exercised the option to continue with the associated Passenger Self-Screening Checkpoint into a detailed prototype design phase.

APM Human Services announced that it has agreed to acquire Equus Workforce Solutions. Equus is a market-leading provider of employment services in the US. The services that Equus delivers include assisting the unemployed find employment, vocational rehabilitation, disability determination, training and education. The acquisition increases APM's scale in the US with a combined footprint of 42 states and 4,000 US team members, enhancing APM's ability to grow in the US market.

Telix announced that it is withdrawing its application for European regulatory approval of the company's prostate imaging product Illucix after European regulatory authorities requested additional manufacturing data late in the approval process. This development was unexpected given the product has received approval in the US and Australia. While the company expects to be in a position to provide the additional data, it was not able to do so within the allotted time. Resubmission is likely to delay the launch of the product in Europe by around 12 months.

Iress downgraded CY22 profit guidance due to challenging macro conditions which are delaying the conversion of new sales opportunities, especially in the UK.

At month end, the portfolio held 46 stocks and cash of 8.5%.

At September end, the weighted average Perennial-derived Environmental, Social, Governance and Engagement ("ESGE") Score of the Fund was 7.3 which is 28% higher than the benchmark ESGE Score of 5.7.

## Contact Us

Level 27, 88 Phillip Street Sydney NSW 2000

1300 088 660

hello@invest.com.au

www.invest.com.au

The Responsible Entity is Perennial Investment Management Limited ABN 13 108 747 637, AFSL: 275101. The Investment Manager is Perennial Better Future Pty Limited ABN 45 647 633 065 | CAR 1293136 of Perennial Value Management Limited ABN 22 090 879 044, AFSL 247293. This report has been prepared by ETF Investments Australia Pty Ltd trading as elinvest Australia ("elinvest") ABN: 88 618 802 912, as the corporate authorised representative of Perennial Investment Management Limited. This report is for information purposes only. Accordingly, reliance should not be placed on this information as the basis for making an investment, financial or other decision. This information does not take into account your investment objectives, particular needs or financial situation. While every effort has been made to ensure the information is accurate; its accuracy, reliability or completeness is not guaranteed. Past performance is not a reliable indicator of future performance. The current relevant product disclosure statement can be found at [www.invest.com.au/IMPQ](http://www.invest.com.au/IMPQ) and you can find the IMPQ TMD at [www.invest.com.au/targetmarketdeterminations/](http://www.invest.com.au/targetmarketdeterminations/). No distribution of this material will be made in any jurisdiction where such distribution is not authorised or is unlawful.

The rating issued 09/2021 published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit [lonsec.com.au](http://lonsec.com.au) for ratings information and to access the full report. ©2022 Lonsec. All rights reserved.

The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) ("Zenith") rating (assigned 02/2022) referred to in this document is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at <https://www.zenithpartners.com.au/RegulatoryGuidelines>

## ESG Activity

Our ESG activity during the month included:

- A meeting with PEXA where we discussed the company's approach to Reconciliation, GHG Emissions and flexible working
- A dedicated ESG call with Calix in which we discussed our thoughts on ESG & Sustainability reporting as applicable to Calix
- A meeting with Chorus at which we discussed gender diversity in the management team including the principles of the 40:40 Vision. We also discussed GHG Emissions and modern slavery.
- A meeting with KMD Brands at which we discussed the company's progress in expanding BCorp accreditation to the Rip Curl brand
- Alpha HPA appointed a female non-executive director to the board

## Top 5 Portfolio Positions

	IMPQ	Index
Meridian Energy Ltd	4.8%	0.0%
Spark New Zealand Ltd	4.4%	0.5%
Sims Ltd	4.3%	1.0%
Chorus Ltd	4.2%	1.4%
Integral Diagnostics	3.9%	0.3%



## Better Future and ESG Team

Damian Cottier – Portfolio Manager

Emilie O'Neill – Co-Head ESG & Equities Analyst